Skip to main content
Feb 28, 2019

Northwest Biotherapeutics hires former buy-sider as new IR head

David Innes joins company at ‘pivotal time’ in its history

Maryland-based Northwest Biotherapeutics has named David Innes as its vice president of investor relations.

Innes brings more than 31 years of experience in managing portfolios at Wall Street firms and a degree in biology, says Northwest Biotherapeutics in a statement, and joins at a ‘pivotal time’ in the firm’s history.

Northwest is currently developing personalized immune therapies for solid tumor cancers and Innes will further strengthen the relationships with both current and prospective retail and institutional shareholders.

For the last decade, Innes was senior director of investments at Oppenheimer, where he managed more than $175 mn in assets, focusing on emerging biotech companies, including as an adviser to many shareholders at Northwest Biotherapeutics. Prior to Oppenheimer, he spent 20 years at UBS, including 10 years as vice president of investments.

Linda Powers, CEO of Northwest, says in the statement: ‘We are pleased to have someone of Dave’s experience in the biotech investment community joining us.’